张岩
特聘研究员 硕士生导师
教育背景
中国科学院大学（博士）
研究领域
研究方向：结构生物学、AI辅助药物设计、药物化学、计算化学
主要从事创新药物设计研究。针对肿瘤等疾病尚未满足的临床需求，揭示创新药物靶标的结构及功能，进而开展小分子先导化合物的发现与优化研究。从人工智能和计算机辅助药物设计出发，结合药物化学、结构生物学及化学生物学，筛选、设计并合成具有疾病干预功能和良好成药性的先导化合物，为创新药物研究奠定基础。获国家及省部级项目资助7项，参与科技部国家重点研发计划、国家重大专项计划、中科院国际合作项目等7项。申请专利40余项，其中已有18项专利授权，已有4项专利成功转化。
电子邮件
zhangyana@gdpu.edu.cn
个人简介
2016.09-2019.06 中国科学院广州生物医药与健康研究院 药物化学 博士
2019.07-2021.06 中国科学院广州生物医药与健康研究院 博士后
2021.07-2026.02 中国科学院广州生物医药与健康研究院 副研究员
2026.03-至今 广东药科大学，生命科学与生物制药学院 特聘研究员，硕士生导师
社会任职：
广东省药学会药物化学专业委员会，委员
广东省药学会海洋药物专业委员会，委员
Acta Materia Medica杂志青年编委
获奖及荣誉：
2018年度广东省自然科学奖二等奖（第二完成人）
2019年获得中国科学院特别研究助理称号
2019年度中国科学院优秀毕业生
2019年度北京市普通高等学校优秀毕业生
2019年度地奥奖学金二等奖
代表论著：
累计在Nat Med、Acta Pharm Sin B、J Med Chem，等杂志上发表SCI论文49篇，通讯及第一作者论文20篇。
[1] Chen, Z#.; Zhang, C#.; Shen, H#.; Xu, H.; Hang, Y.; Dong, R.; Tang, X.; Chai, S.; Li, J.; Xu, J.; Zhang, Y*.; Wu, X*.; Xu, Y*. Key Imidazolyl Groups That Induce Phenylalanine Flipping Enhance the Efficacy of Oral BRD9 Inhibitors for AML Treatment. Acta Pharmaceutica Sinica B 2025, 15, 6546-6570.
[2] Shen, H.; Xu H.; Jin, W.; Wu, T.; Hu, J.; Zhang, C.; Zhong, Z.; Li, J.; Mao, R.; Zhang, S.; Zhang, X.; Wu, X.; Smaill, J.; Xu, J.; Zhang, Y*.; Xu, Y*. Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-resistant Prostate Cancer. Journal of Medicinal Chemistry 2025, 68, 1553-1571.
[3] Hu, J#.; Tang, X#.; Luo, G#.; Zhang, C.; Wu, T.; Wang, C.; Shen, H.; Zhao, X.; Wu, X.; Smaill, JB.; Xu, Y*.; Zhang, Y*.; Xiang, Q*. Discovery of 5-imidazole-3-methylbenz[d]isoxazole derivatives as potent and selective CBP/p300 bromodomain inhibitors for the treatment of acute myeloid leukemia. Acta Pharmacologica Sinica 2025, 46, 1706-1721.
[4] Hu, J#.; Xu, H#.; Wu, T#.; Zhang, C.; Shen, H.; Dong, R.; Hu, Q.; Xiang, Q.; Chai, S.; Luo, G.; Chen, X.; Huang, Y.; Zhao, X.; Peng, C.; Wu, X.; Lin, B.; Zhang, Y*.; Xu, Y*. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. Journal of Medicinal Chemistry 2024, 67, 6952-6986.
[5] Wu, X#,*.; Luo, X#.; Li, C.; Zhao, X.; Zhang, C.; Chen, X.; Lu, Z.; Wu, T.; Yu, H.; Peng, C.; Hu, Q.; Shen, H.; Xu. Y*.; Zhang, Y*. Discovery and pharmacological characterization of 1,2,3,4-tetrahydroquinoline derivatives as RORγ inverse agonists against prostate cancer. Acta Pharmacologica Sinica 2024, 45, 1964-1977.
[6] Li, J.; Zhu, R.; Zhuang, X.; Zhang, C.; Shen, H.; Wu, X.; Zhang, M.; Huang, C.; Xiang, Q.; Zhao, L.; Xu, Y*.; Zhang, Y*. Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer. Bioorganic Chemistry 2023, 135, 106495.
[7] Xiang, Q#.; Wu, T#.; Zhang, C.; Wang, C.; Xu, H.; Hu, Q.; Hu, J.; Luo, G.; Zhuang, X.; Wu, X.; Zhang, Y*.; Xu, Y*. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia, Bioorganic Chemistry 2024, 142, 106950.
[8] Zhang, M#.; Luo, X#.; Zhang, C.; Wang, C.; Wu, X.; Xiang, Q.; Xu, Y*.; Zhang, Y*. Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia. Acta Pharmacologica Sinica 2022, 43:2735-2748.
[9] Xu, H.; Luo, G.; Wu, T.; Hu, J.; Wang, C.; Wu, X.; Zhang, Y*.; Xu, Y*.; Xiang, Q*. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain. Biochemical and Biophysical Research Communications 2022, 623, 17-22.
[10] Wu, T#.; Xiang, Q#.; Wang, C#.; Wu, C.; Zhang, C.; Zhang, M.; Liu, Z.; Zhang, Y*.; Xiao, L*.; Xu Y*. Y06014 is a selective BET inhibitor for the treatment of prostate cancer. Acta Pharmacologica Sinica 2021, 42, 2120-2131.
[11] Song, Y.; Xue, X.; Wu, X.; Wang, R.; Xing, Y.; Yan, W.; Zhou, Y.; Qian, C-N.; Zhang, Y*.; Xu, Y.*; Identification of N-phenyl-2-(N-phenylphenylsulfonamido) Acetamides as New RORγ Inverse Agonists: Virtual Screening, Structure-based Optimization, and Biological Evaluation. European Journal of Medicinal Chemistry 2016, 116, 13-26.
[12] Ma K#, Jin W#, Zhang Y#, Lu Z#, Zhuang X, Li J, Jing X, Wang J, Li L, Zhou Y, Li X, Xu T, Xu J, Ma J, Deng J*, Zhai X*, Lin B*, Xu Y*, Shen H*. Discovery of novel indole derivatives as LRH-1 antagonists for the treatment of castration resistant prostate cancer. European Journal of Medicinal Chemistry 2026, 308, 118681.
[13] Wu, X#.; Shen, H#.; Zhang, Y#.; Wang, C.; Li, Q.; Zhang, C.; Zhuang, X.; Li, C.; Shi, Y.; Xing, Y.; Xiang, Q.; Xu, J.; Wu, D.; Liu, J.; Xu, Y*. Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist. Journal of Medicinal Chemistry 2021, 64, 8775-8797.
[14] Chen, Z#.; Yang, H#.; Zhang, Y#.; Lyu, X.; Shi, Q.; Zhang, C.; Wang, X.; Wang, Z.; Zhang, Y.; Deng, Y.; Wang, Y.; Huang, Y.; Xu, Y*.; Huang, X*.; Li, Y*. Discovery of CZL-046 with an (S)-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma. Journal of Medicinal Chemistry 2024, 67, 18606-18628.
[15] Zhang, Y#.; Wu, X#.; Xue, X#.; Li, C.; Wang, J.; Wang, R.; Zhang, C.; Wang, C.; Shi, Y.; Zou, L.; Li, Q.; Huang, Z.; Hao, X.; Loomes, K.; Wu, D.; Chen, H.; Xu, J.; Xu, Y*. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry 2019, 62, 4716-4730.
[16] Zhang, M#.; Zhang, Y#.; Song, M#.; Xue, X.; Wang, J.; Wang, C.; Zhang, C.; Li, C.; Xiang, Q.; Zou, L.; Wu, X.; Wu, C.; Dong, B.; Xue, W.; Zhou, Y.; Chen, H.; Wu, D.; Ding, K.; Xu, Y*. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Journal of Medicinal Chemistry 2018. 61, 3037-3058.
[17] Xiang, Q#.; Zhang, Y#.; Li, J#.; Xue, X.; Wang, C.; Song, M.; Zhang, Z.; Wang, R.; Li, C.; Wu, C.; Zhou, Y.; Yang, X.; Li, G.; Ding, K.; Xu, Y*. Y08060: A selective BET inhibitor for treatment of prostate cancer. ACS Medicinal Chemistry Letters 2018, 9, 262-267.
[18] Xue, X#.; Zhang, Y#.; Liu, Z.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu, Y*. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Journal of Medicinal Chemistry 2016. 59, 1565-1579.
[19] Zhang, Y.; Luo, X.; Wu, D*.; Xu, Y*. ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacologica Sinica 2015, 36, 71-87.
[20] Zhang, Y#.; Xue, X#.; Jin, X.; Song, Y.; Li, J.; Luo, X.; Song, M.; Yan, W.; Song, H.; Xu, Y*. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORgamma inhibitors using virtual screening, synthesis and biological evaluation. European Journal of Medicinal Chemistry 2014, 78, 431-441.
